News | 23 January 2024
Glenmark Life Sciences posts Q3 FY24 PAT at Rs. 118.76 Cr
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Tatva Chintan Pharma Chem has reported total income of Rs. 85.41 crores during the period ended December 31, 2023
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Automated parallel capillary electrophoresis system simplifies protein analysis
Collaboration streamlines patient access to oncology clinical trials
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
Subscribe To Our Newsletter & Stay Updated
